These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Reconstitution of interleukin 2 with albumin for infusion. Miles DW; Bird CR; Wadhwa M; Summerhayes M; Balkwill FR; Thorpe R; Rubens RD Lancet; 1990 Jun; 335(8705):1602-3. PubMed ID: 1972528 [No Abstract] [Full Text] [Related]
3. Reconstitution of interleukin-2 with albumin for infusion. Hamblin T Lancet; 1990 Jul; 336(8709):251. PubMed ID: 1973802 [No Abstract] [Full Text] [Related]
4. Toxicity and reconstitution of recombinant interleukin-2 with albumin. Miles DW; Longhurst SJ; Harper PG; Balkwill FR Lancet; 1991 Dec; 338(8780):1464. PubMed ID: 1683452 [No Abstract] [Full Text] [Related]
5. Plasma concentration profiles of human recombinant interleukin-2 (HrIL-2) in the rat following administration by various systemic routes. Colburn WA; Hakimi J; Bekersky I Drug Metab Dispos; 1987; 15(3):429-31. PubMed ID: 2886323 [No Abstract] [Full Text] [Related]
7. The toxicity of recombinant human interleukin-2 in rats following intravenous infusion. Matory YL; Chang AE; Lipford EH; Braziel R; Hyatt CL; Rosenberg SA J Natl Med Assoc; 1987 May; 79(5):537-41. PubMed ID: 3495666 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of teceleukin (recombinant human interleukin-2) after intravenous or subcutaneous administration to patients with cancer. Gustavson LE; Nadeau RW; Oldfield NF J Biol Response Mod; 1989 Aug; 8(4):440-9. PubMed ID: 2787839 [TBL] [Abstract][Full Text] [Related]
9. Administration of high-dose recombinant interleukin 2 after autologous bone marrow transplantation in patients with neuroblastoma: toxicity, efficacy and survival. A Lyon-Marseille-Curie-east of France Group Study. Michon J; Négrier S; Coze C; Mathiot C; Frappaz D; Oskam R; Pacquement H; Quintana E; Bouffet E; Bernard JL Prog Clin Biol Res; 1994; 385():293-300. PubMed ID: 7972223 [No Abstract] [Full Text] [Related]
10. [A first trial of the use of human recombinant interleukin (rIL-2) in patients with tumorous diseases]. Grinev MV; Tsibin IuN; Tarelkina MN; Gromov MI; Shirokov DM; Pivovarova LP; Frolov GM; Razumova NK; Masiianskaia TI; Ariskina OB Vestn Khir Im I I Grek; 1995; 154(2):57-60. PubMed ID: 8540190 [TBL] [Abstract][Full Text] [Related]
11. Renal haemodynamics, sodium and water reabsorption during continuous intravenous infusion of recombinant interleukin-2. Geertsen PF; von der Maase H; Olsen NV; Fogh-Andersen N; Nielsen SL; Leyssac PP Clin Sci (Lond); 1998 Jul; 95(1):73-81. PubMed ID: 9662488 [TBL] [Abstract][Full Text] [Related]
12. Intraperitoneal infusion of recombinant interleukin-2 in malignant ascites in patients with gastrointestinal and ovarian cancer. Bertoglio S; Melioli G; Baldini E; Catturich A; Sertoli MR; Civalleri D; Percivale P; Meier W; Galazka A; Badellino F Acta Med Austriaca; 1989; 16(3-4):81-3. PubMed ID: 2609918 [TBL] [Abstract][Full Text] [Related]
13. Treatment of renal cell carcinoma with systemic administration of intermediate doses of recombinant human interleukin-2 alone. Recombinant Human Interleukin-2 (S-6820) Research Group on Renal Cell Carcinoma. Aso Y; Tazaki H; Umeda T; Marumo K Prog Clin Biol Res; 1989; 303():681-8. PubMed ID: 2675018 [No Abstract] [Full Text] [Related]
14. Clinical application of continuous infusion of recombinant interleukin-2. West WH Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S11-5. PubMed ID: 2627985 [TBL] [Abstract][Full Text] [Related]
15. [A phase I study of recombinant interleukin 2 (S6820)]. Takaku F Gan To Kagaku Ryoho; 1988 Dec; 15(12):3271-6. PubMed ID: 3058043 [TBL] [Abstract][Full Text] [Related]